News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2015Sites scheduling additional patients in HPPI’s study of proposed treatment for basal cell carcinoma nevus syndrome
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 29, 2015) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Aug 21, 2015Enrollment commenced in HPPI’s Phase II(b) study of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – August 21, 2015 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
May 18, 2015HedgePath to shortly commence Phase II(b) skin cancer trial using Mayne Pharma’s SUBATM-Itraconazole
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (May 18, 2015) – HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Dec 16, 2014HPPI to commence Phase IIb study in first quarter 2015 of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – December 16, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Nov 18, 2014Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – November 18, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...